CareDx Reports First Quarter 2026 Financial Results
CareDx, Inc. announced its financial results for the first quarter ended March 31, 2026, reporting a revenue of $118 million, which is a 39% increase year-over-year. The revenue from testing services was reported at $91 million.
BRISBANE, Calif.–(BUSINESS WIRE)–CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights Revenue of $118 million, an increase of 39% year-over-year Testing services revenue of $91 m